Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Sionna Therapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Sionna Therapeutics, Inc. (SION) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sionna Therapeutics, Inc. (“Sionna” or “the Company”) (NASDAQ: SION). Investors who purchased Sionna securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Sionna has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On August 10, 2026, Sionna reported topline data from its PreciSION CF Phase 2a trial and provided a corporate update. Among other items, Sionna announced a primary endpoint miss and that the Company will not advance SION-719 as an add-on to standard of care. Following this news, Sionna’s stock price dropped and continues to trade below the IPO price at this time.
What Should Sionna Therapeutics, Inc. (SION) Investors Do?
If you are aware of any facts relating to this investigation or purchased Sionna securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Did Sionna Therapeutics, Inc. (SION) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”